



Drugs for neuropathic pain can be helpful in appropriately selected patients.
Non-pharmacologic therapies, including exercise and weight loss, can reduce the burden of pain.
All provide equal pain relief,4 but have different cardiac and GI risk based on degree of COX-1 versus COX-2 inhibition.
Naproxen (Naprosyn, Aleve, and generics) has the lowest risk of cardiac side effects.
For patients at increased risk of GI toxicity, add a proton pump inhibitor (PPI) such as omeprazole (Prilosec and generics) or an H2 blocker to the NSAID.6 For those at highest risk of GI side effects, if an NSAID must be used, celecoxib can be combined with a PPI.7
|
GI toxicity risk factors:5
|
Any dose of aspirin will reverse the GI protective effects of celecoxib. For patients who need both a cardioprotective aspirin and an NSAID, prescribe naproxen (with an H2 blocker or PPI to minimize GI risk if needed). Any NSAID should be taken at least 8 hours before or 30 minutes after aspirin to prevent the NSAID from interfering with aspirin’s cardiac benefit.7
Most opiates have equal analgesic efficacy, adjusting for dose.
Opiates are very effective in pain relief, but come with important risks.
Addiction, dependence, and accidental overdose are all potential problems with chronic opiate use.
Reduce risk of opiate misuse with specific prevention measures.9
When starting:
During treatment:
Get ahead of bowel problems. Start a bowel regimen proactively when initiating an opiate.
Both are as effective as other low-potency opiates (e.g. Schedule III agents).11,12
| Comments |
Opiate-like agents better |
Opiates better | |
| Minor side effects | opiate-like ages have lower rate of nausea, vomiting, loss of appetite, and dizziness | X | |
| Major side effects | opiate-like agents have lower rate of fractures and safety events requiring hospitalization | X | |
|
Drug interactions |
cannot combine opiate-like agents with any serotenergic agents (TCAs, SNRIs, SSRIs) | X | |
| Contraindications | tramadol cannot be used in patients with suicide or seizure risk | X | |
| Long-term safety data |
tapentadol was FDA approved 2009 |
X | |
| Use in renal or liver impairment | tapentadol cannot be used in patients with severe liver or renal impairment | X |
Some anti-convulsants and antidepressants are effective in treating the neuropathic component of pain, though their use is often limited by adverse effects.
Comparative efficacy of selected antidepressants and anti-convulsants in the treatment of diabetic neuropathy.13
| Agent (# high quality trials) | % pain reduction, compared to placebo | Common adverse effects |
|
Amitriptyline (3)
|
58-63% |
dry mouth urinary retention hypotension cardiac conduction abnormality |
|
Venlafaxine (2) Duloxetine (3) |
8-23% |
decreased appetite constipation nausea vomiting |
|
Pregablin (4) Gabapentin (2) |
11-13% |
confusion edema |
Combining an opiate with a neuropathic agent in diabetic neuropathy can reduce pain levels better than either drug alone, at low doses.14
Other approaches can have modest effects in reducing pain.
| Treatment | Advantage | Disadvantage |
| Local steroid injections (joint pain) |
injection lasts ~4 weeks minimal systemic effects |
invasive; requires expertise |
| Local viscosupplement injections (e.g. hyaluronan, joint pain) |
injection lasts ~5-13 weeks minimal systemic effects |
invasive; requires expertise high cost |
| Topical capsaicin and salicylate products (local superficial pain) |
over-the-counter low cost minimal systemic effects may be large placebo component |
local skin reactions common |
| Topical lidocaine patch (local superficial pain) | minimal systemic effects |
effective only for superficial, not deep pain not always covered |
| Topical diclofenac (joint pain) |
short-term pain relief (<2 weeks) minimal side effects |
no long-term pain relief high cost |
| Glucosamine/chondroitin oral tablets |
over-the-counter low cost |
minimally effective not regulated by the FDA |
For many patients with severe degenerative joint disease, replacing a hip or knee can provide substantial relief and end the need for dependence on pain medications. Consider referral to a specialist for worsening DJD.
Non-pharmacologic interventions can also be useful in controlling pain, improving function, or both in osteoarthritis, fibromyalgia, and chronic low back pain.
| Goal | |||
| Condition | Pain control | Improving function | Both |
| Osteoarthritis | quadriceps strengthening | weight loss (combined with exercise) |
Tai Chi therapeutic ultrasound electromagnetic stimulation braces and insoles acupuncture exercise |
| Fibromyalgia |
Cognitive Behavioral Therapy exercise acupuncture |
_ | Tai Chi |
| Chronic Low Back Pain |
spinal manipulation massage Cognitive Behavioral Therapy |
_ | exercise |
References: 1. IOM. Relieving pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2011. 2. Won AB, Lapane KL, Vallow S, Schein J, Morris JN, Lipsitz LA. Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc. Jun 2004;52(6):867-874. 3. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006(1):CD004257. 4. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008(1):CD000396. 5. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. Mar 27 2007;115(12):1634-1642. 6. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002(4):CD002296. 7. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. May 12 2007;369(9573):1621-1626. 8. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. Apr 6;305(13):1315-1321. 9. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. Feb 2009;10(2): 113-130. 10. Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. Jun 2006;21(6):652-655. 11. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. Dec 13;170(22):1979-1986. 12. Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a doubleblind comparative trial. Clin J Pain. Jan 2008;24(1):1-4. 13. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. Jul 14 2007;335(7610):87. 14. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. Mar 31 2005;352(13):1324-1334.